ALX-5407

ALX-5407 (also known as NFPS) is a potent, selective, and near-irreversible inhibitor of the glycine transporter 1 (GlyT1). By inhibiting GlyT1, ALX-5407 increases extracellular glycine concentrations in the synaptic cleft, where glycine acts as a necessary co-agonist at the strychnine-insensitive site of the N-methyl-D-aspartate (NMDA) receptor. This modulation of NMDA receptor transmission is being investigated for its potential to treat various neuropsychiatric and neurological conditions. Preclinical research, including studies in MPTP-lesioned marmosets, has demonstrated that ALX-5407 can significantly reduce the severity of levodopa-induced dyskinesia and psychosis-like behaviors in Parkinson's disease models without compromising the anti-parkinsonian efficacy of L-DOPA. Historically, the compound has also been a key tool in studying the negative symptoms of schizophrenia.

Other names

(R)-NFPS(R)-(N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl])sarcosine